Parathyroid hormone

PTH
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1BWX, 1ET1, 1FVY, 1HPH, 1HPY, 1HTH, 1ZWA, 1ZWB, 1ZWD, 1ZWE, 1ZWF, 1ZWG, 2L1X, 3C4M
Identifiers
Aliases	PTH , PTH1, parathyroid hormone, Parathyroid hormone, FIH1
External IDs	OMIM: 168450 MGI: 97799 HomoloGene: 266 GeneCards: PTH
Gene location (Human) Chr. Chromosome 11 (human) [1] Band 11p15.3 Start 13,492,054 bp [1] End 13,496,181 bp [1]
Gene location (Mouse) Chr. Chromosome 7 (mouse) [2] Band 7 F1|7 59.19 cM Start 112,984,787 bp [2] End 112,987,777 bp [2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in retinal pigment epithelium muscle tissue body of stomach fundus embryo uterine tube smooth muscle tissue ganglionic eminence mammary gland breast Top expressed in trachea parathyroid thymus morula esophagus superior colliculus medulla oblongata pancreas submandibular gland neural tube More reference expression data BioGPS More reference expression data
Gene ontology Molecular function transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding hormone activity parathyroid hormone receptor binding type 1 parathyroid hormone receptor binding protein N-terminus binding receptor ligand activity peptide hormone receptor binding DNA-binding transcription factor activity, RNA polymerase II-specific protein binding Cellular component intracellular anatomical structure extracellular region extracellular space Biological process positive regulation of signal transduction positive regulation of cell proliferation in bone marrow positive regulation of osteoclast proliferation response to fibroblast growth factor hormone-mediated apoptotic signaling pathway cAMP metabolic process response to ethanol response to parathyroid hormone skeletal system development positive regulation of ossification response to lead ion response to nutrient levels G protein-coupled receptor signaling pathway response to vitamin D negative regulation of apoptotic process in bone marrow cell negative regulation of transcription by RNA polymerase II cellular macromolecule biosynthetic process cellular calcium ion homeostasis homeostasis of number of cells within a tissue response to cadmium ion Rho protein signal transduction positive regulation of glucose import positive regulation of glycogen biosynthetic process bone resorption positive regulation of bone mineralization regulation of gene expression positive regulation of transcription by RNA polymerase II cell-cell signaling activation of phospholipase C activity negative regulation of chondrocyte differentiation positive regulation of inositol phosphate biosynthetic process negative regulation of bone mineralization involved in bone maturation regulation of signaling receptor activity adenylate cyclase-activating G protein-coupled receptor signaling pathway calcium ion transport magnesium ion homeostasis bone mineralization phosphate ion homeostasis calcium ion homeostasis negative regulation of calcium ion transport Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 5741 19226 Ensembl ENSG00000152266 ENSMUSG00000059077 UniProt P01270 Q9Z0L6 RefSeq (mRNA) NM_000315 NM_001316352 NM_020623 RefSeq (protein) NP_000306 NP_001303281 NP_065648 Location (UCSC) Chr 11: 13.49 – 13.5 Mb Chr 7: 112.98 – 112.99 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Parathyroid hormone (PTH), also called parathormone or parathyrin, is a peptide hormone secreted by the parathyroid glands that regulates the serum calcium concentration through its effects on bone, kidney, and intestine. ^[5]

PTH influences bone remodeling, which is an ongoing process in which bone tissue is alternately resorbed and rebuilt over time. PTH is secreted in response to low blood serum calcium (Ca²⁺) levels. PTH indirectly stimulates osteoclast activity within the bone matrix (osteon), in an effort to release more ionic calcium (Ca²⁺) into the blood to elevate a low serum calcium level. The bones act as a (metaphorical) "bank of calcium" from which the body can make "withdrawals" as needed to keep the amount of calcium in the blood at appropriate levels despite the ever-present challenges of metabolism, stress, and nutritional variations. PTH is "a key that unlocks the bank vault" to remove the calcium.

PTH is secreted primarily by the chief cells of the parathyroid glands. The gene for PTH is located on chromosome 11. It is a polypeptide containing 84 amino acids, which is a prohormone. It has a molecular mass around 9500 Da. ^[6] Its action is opposed by the hormone calcitonin.

There are two types of PTH receptors. Parathyroid hormone 1 receptors, activated by the 34 N-terminal amino acids of PTH, are present at high levels on the cells of bone and kidney. Parathyroid hormone 2 receptors are present at high levels on the cells of central nervous system, pancreas, testes, and placenta. ^[7] The half-life of PTH is about 4 minutes. ^[8]

Disorders that yield too little or too much PTH, such as hypoparathyroidism, hyperparathyroidism, and paraneoplastic syndromes can cause bone disease, hypocalcemia, and hypercalcemia.

Structure

hPTH-(1-84) crystallizes as a slightly bent, long, helical dimer. The extended helical conformation of hPTH-(1-84) is the likely bioactive conformation. ^[9] The N-terminal fragment 1-34 of parathyroid hormone (PTH) has been crystallized and the structure has been refined to 0.9 Å resolution.

helical dimer structure of hPTH-(1-34)

Function

Regulation of serum calcium

The parathyroid gland releases PTH which keeps calcium in homeostasis.

Main article: Calcium metabolism

A diagrammatic representation of the movements of calcium ions into and out of the blood plasma (the central square labeled PLASMA Ca ) in an adult in calcium balance:
The widths of the red arrows indicating movement into and out of the plasma are roughly in proportion to the daily amounts of calcium moved in the indicated directions.
The size of the central square in not in proportion to the size of the diagrammatic bone, which represents the calcium present in the skeleton, and contains about 25,000 mmol (or 1 kg) of calcium compared to the 9 mmol (360 mg) dissolved in the blood plasma.
The differently colored narrow arrows indicate where the specified hormones act, and their effects (“+” means stimulates; “-“ means inhibits) when their plasma levels are high.
PTH is parathyroid hormone, 1,25 OH VIT D₃ is calcitriol or 1,25 dihydroxyvitamin D₃, and CALCITONIN is a hormone secreted by the thyroid gland when the plasma ionized calcium level is high or rising.
The diagram does not show the extremely small amounts of calcium that move into and out of the cells of the body, nor does it indicate the calcium that is bound to the extracellular proteins (in particular the plasma proteins) or to plasma phosphate.

Parathyroid hormone regulates serum calcium through its effects on bone, kidney, and the intestine: ^[5]

In bone, PTH enhances the release of calcium from the large reservoir contained in the bones. ^[16] Bone resorption is the normal destruction of bone by osteoclasts, which are indirectly stimulated by PTH. Stimulation is indirect since osteoclasts do not have a receptor for PTH; rather, PTH binds to osteoblasts, the cells responsible for creating bone. Binding stimulates osteoblasts to increase their expression of RANKL and inhibits their secretion of osteoprotegerin (OPG). Free OPG competitively binds to RANKL as a decoy receptor, preventing RANKL from interacting with RANK, a receptor for RANKL. The binding of RANKL to RANK (facilitated by the decreased amount of OPG available for binding the excess RANKL) stimulates osteoclast precursors, which are of a monocyte lineage, to fuse. The resulting multinucleated cells are osteoclasts, which ultimately mediate bone resorption. Estrogen also regulates this pathway through its effects on PTH. Estrogen suppresses T cell TNF production by regulating T cell differentiation and activity in the bone marrow, thymus, and peripheral lymphoid organs. In the bone marrow, estrogen downregulates the proliferation of hematopoietic stem cells through an IL-7 dependent mechanism. ^[17]

In the kidney, around 250 mmol of calcium ions are filtered into the glomerular filtrate per day. Most of this (245 mmol/d) is reabsorbed from the tubular fluid, leaving about 5 mmol/d to be excreted in the urine. This reabsorption occurs throughout the tubule (most, 60-70%, of it in the proximal tubule), except in the thin segment of the loop of Henle. ^[11] Circulating parathyroid hormone only influences the reabsorption that occurs in the distal tubules and the renal collecting ducts ^[11] (but see Footnote ^{[nb 1]} ). A more important effect of PTH on the kidney is, however, its inhibition of the reabsorption of phosphate (HPO₄²⁻) from the tubular fluid, resulting in a decrease in the plasma phosphate concentration. Phosphate ions form water-insoluble salts with calcium. Thus, a decrease in the phosphate concentration of the blood plasma (for a given total calcium concentration) increases the amount of calcium that is ionized. ^{[20] [21]} A third important effect of PTH on the kidney is its stimulation of the conversion of 25-hydroxy vitamin D into 1,25-dihydroxy vitamin D (calcitriol), which is released into the circulation. This latter form of vitamin D is the active hormone which stimulates calcium uptake from the intestine. ^[22]

Via the kidney, PTH enhances the absorption of calcium in the intestine by increasing the production of activated vitamin D. Vitamin D activation occurs in the kidney. PTH up-regulates 25-hydroxyvitamin D₃ 1-alpha-hydroxylase, the enzyme responsible for 1-alpha hydroxylation of 25-hydroxy vitamin D, converting vitamin D to its active form (1,25-dihydroxy vitamin D). This activated form of vitamin D increases the absorption of calcium (as Ca²⁺ ions) by the intestine via calbindin.

PTH was one of the first hormones to be shown to use the G-protein adenylyl cyclase second messenger system.

Regulation of serum phosphate

PTH reduces the reabsorption of phosphate from the proximal tubule of the kidney, ^[23] which means more phosphate is excreted through the urine.

However, PTH enhances the uptake of phosphate from the intestine and bones into the blood. In the bone, slightly more calcium than phosphate is released from the breakdown of bone. In the intestines, absorption of both calcium and phosphate is mediated by an increase in activated vitamin D. The absorption of phosphate is not as dependent on vitamin D as is that of calcium. The result of PTH release is a small net drop in the serum concentration of phosphate.

Vitamin D synthesis

PTH upregulates the activity of 1-α-hydroxylase enzyme, which converts 25-hydroxycholecalciferol, the major circulating form of inactive vitamin D, into 1,25-dihydroxycholecalciferol, the active form of vitamin D, in the kidney.

Interactive pathway map

Click on genes, proteins and metabolites below to link to respective articles. ^{[§ 1]}

[[File:

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

[[

]]

|alt=Vitamin D Synthesis Pathway (view / edit)]]

Vitamin D Synthesis Pathway (view / edit)

1. The interactive pathway map can be edited at WikiPathways: "VitaminDSynthesis_WP1531".

Regulation of PTH secretion

Secretion of parathyroid hormone is determined chiefly by serum ionized calcium concentration through negative feedback. Parathyroid cells express calcium-sensing receptors on the cell surface. PTH is secreted when [Ca²⁺] is decreased (calcitonin is secreted when serum calcium levels are elevated). The G-protein-coupled calcium receptors bind extracellular calcium and may be found on the surface on a wide variety of cells distributed in the brain, heart, skin, stomach, C cells, and other tissues. In the parathyroid gland, high concentrations of extracellular calcium result in activation of the Gq G-protein coupled cascade through the action of phospholipase C. This hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to liberate intracellular messengers IP3 and diacylglycerol (DAG). Ultimately, these two messengers result in a release of calcium from intracellular stores into the cytoplasmic space. Hence a high extracellular calcium concentration leads to an increase in the cytoplasmic calcium concentration. In contrast to the mechanism that most secretory cells use, this high cytoplasmic calcium concentration inhibits the fusion of vesicles containing granules of preformed PTH with the membrane of the parathyroid cell, and thus inhibits release of PTH.

In the parathyroids, magnesium serves this role in stimulus-secretion coupling. A mild decrease in serum magnesium levels stimulates the reabsorptive activity PTH has on the kidneys. Severe hypomagnesemia inhibits PTH secretion and also causes resistance to PTH, leading to a form of hypoparathyroidism that is reversible. ^[24]

Stimulators

• Decreased serum [Ca²⁺].
• Mild decreases in serum [Mg²⁺].
• An increase in serum phosphate (increased phosphate causes it to complex with serum calcium, forming calcium phosphate, which reduces stimulation of Ca-sensitive receptors (CaSr) that do not sense calcium phosphate, triggering an increase in PTH).
• Adrenaline
• Histamine

Inhibitors

• Increased serum [Ca²⁺].
• Severe decreases in serum [Mg²⁺], which also produces symptoms of hypoparathyroidism (such as hypocalcemia). ^[25]
• Calcitriol
• Increase in serum phosphate. Fibroblast growth factor-23 (FGF23) is produced in osteoblasts (from bone) in response to increases in serum phosphate (Pi). It binds to the fibroblast growth factor receptor of the parathyroid and suppresses PTH release. This may seem contradictory because PTH actually helps rid the blood of phosphates but it is also causes release of phosphate into the blood from bone resorption. FGF23 inhibits PTH and then takes its place helping inhibit re-absorption of phosphate in the kidney without the phosphate releasing effect on bones. ^{[26] [27]}

Disorders

Hyperparathyroidism, the presence of excessive amounts of parathyroid hormone in the blood, occurs in two very distinct sets of circumstances. Primary hyperparathyroidism is due to autonomous, abnormal hypersecretion of PTH from the parathyroid gland, while secondary hyperparathyroidism is an appropriately high PTH level seen as a physiological response to hypocalcemia. A low level of PTH in the blood is known as hypoparathyroidism and is most commonly due to damage to or removal of parathyroid glands during thyroid surgery.

There are a number of rare but well-described genetic conditions affecting parathyroid hormone metabolism, including pseudohypoparathyroidism, familial hypocalciuric hypercalcemia, and autosomal dominant hypercalciuric hypocalcemia. Of note, PTH is unchanged in pseudopseudohypoparathyroidism. In osteoporotic women, administration of an exogenous parathyroid hormone analogue (teriparatide, by daily injection) superimposed on estrogen therapy produced increases in bone mass and reduced vertebral and nonvertebral fractures by 45 to 65%. ^[28]

Measurement

PTH can be measured in the blood in several different forms: intact PTH; N-terminal PTH; mid-molecule PTH, and C-terminal PTH, and different tests are used in different clinical situations. The level may be stated in pg/dL or pmol/L (sometimes abbreviated mmol/L); multiply by 0.1060 to convert from pg/dL to pmol/L. ^[29]

A US source states the average PTH level to be 8–51 pg/mL. ^[30] In the UK the biological reference range is considered to be 1.6-6.9 pmol/L. ^[31] Normal total plasma calcium level ranges from 8.5 to 10.2 mg/dL (2.12 mmol/L to 2.55 mmol/L). ^[32]

Interpretive guide

The intact PTH and calcium normal ranges are different for age; calcium is also different for sex. ^{[33] [34]}

Condition	Intact PTH	Calcium
Normal Parathyroid	Normal	Normal
Hypoparathyroidism	Low or Low Normal [note 1]	Low
Hyperparathyroidism
- Primary	High or Normal [note 1]	High
- Secondary	High	Normal or Low
- Tertiary [note 2]	High	High
Non-Parathyroid Hypercalcemia	Low or Low Normal [note 1]	High

1. Low Normal or Normal only for Quest Lab, not LabCorp
2. Both primary and tertiary hyperparathyroidism may have high PTH and high calcium. Tertiary is differentiated from primary hyperparathyroidism by a history of chronic kidney failure and secondary hyperparathyroidism.

Medical uses

Recombinant human parathyroid hormone

This section is an excerpt from Recombinant human parathyroid hormone.[ edit ]

Recombinant human parathyroid hormone, sold under the brand name Preotact among others, is an artificially manufactured form of the parathyroid hormone used to treat hypoparathyroidism (under-active parathyroid glands). ^{[35] [36] [37] [38]} Recombinant human parathyroid hormone is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures. ^[39] A significant reduction in the incidence of vertebral fractures has been demonstrated. ^[39] It is used in combination with calcium and vitamin D supplements. ^{[35] [37]}

The most common side effects include sensations of tingling, tickling, pricking, or burning of the skin (paraesthesia); low blood calcium; headache; high blood calcium; and nausea. ^[36]

Recombinant human parathyroid hormone (Preotact) was approved for medical use in the European Union in April 2006. ^[39] Recombinant human parathyroid hormone (Natpara) was approved for medical use in the United States in January 2015, and in the European Union (as Natpar) in February 2017. ^{[37] [40]}

Teriparatide

This section is an excerpt from Teriparatide.[ edit ]

Parathyroid hormone

Clinical data
Trade names	Forteo, Forsteo
Biosimilars	Bonsity, [41] Kauliv, [42] Livogiva, [43] Osnuvo, [44] Qutavina, [45] Sondelbay, [46] Teribone, [47]
AHFS/Drugs.com	Monograph
MedlinePlus	a603018
License data	EU  EMA:  by INN US  DailyMed:  Teriparatide
Pregnancy category	AU:B3 [48]
Routes of administration	Subcutaneous
ATC code	H05AA02 ( WHO )
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only / Schedule D US: WARNING [49] Rx only [50] EU:Rx only [51] [46] [42]
Pharmacokinetic data
Bioavailability	95%
Metabolism	Liver (nonspecific proteolysis)
Elimination half-life	Subcutaneous: 1 hour
Excretion	Kidney (metabolites)
Identifiers
CAS Number	52232-67-4  Y
PubChem CID	16132393
IUPHAR/BPS	4448
DrugBank	DB06285  Y
ChemSpider	17289052  N
UNII	10T9CSU89I
KEGG	D06078  Y
ChEMBL	ChEMBL525610
Chemical and physical data
Formula	C181H291N55O51S2
Molar mass	4117.77 g·mol−1
3D model (JSmol)	Interactive image
SMILES [H]/N=C(\N)/NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN/C(=N/[H])/N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](Cc4ccccc4)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc5cnc[nH]5)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](Cc6cnc[nH]6)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N
InChI InChI=1S/C181H291N55O51S2/c1-21-96(18)146(236-160(267)114(48-53-141(250)251)212-174(281)132(84-239)232-177(284)143(93(12)13)233-147(254)103(185)82-237)178(285)216-111(45-50-134(187)241)155(262)219-119(65-90(6)7)163(270)213-116(55-62-289-20)158(265)224-124(71-100-79-196-86-203-100)167(274)226-126(73-135(188)242)169(276)217-117(63-88(2)3)148(255)201-81-138(245)205-105(39-27-30-56-182)149(256)223-123(70-99-78-195-85-202-99)166(273)221-121(67-92(10)11)164(271)225-128(75-137(190)244)171(278)231-131(83-238)173(280)214-115(54-61-288-19)157(264)210-112(46-51-139(246)247)153(260)208-109(43-34-60-199-181(193)194)159(266)234-144(94(14)15)175(282)215-113(47-52-140(248)249)156(263)222-122(69-98-77-200-104-38-26-25-37-102(98)104)165(272)220-120(66-91(8)9)161(268)209-108(42-33-59-198-180(191)192)151(258)206-106(40-28-31-57-183)150(257)207-107(41-29-32-58-184)152(259)218-118(64-89(4)5)162(269)211-110(44-49-133(186)240)154(261)228-129(76-142(252)253)172(279)235-145(95(16)17)176(283)229-125(72-101-80-197-87-204-101)168(275)227-127(74-136(189)243)170(277)230-130(179(286)287)68-97-35-23-22-24-36-97/h22-26,35-38,77-80,85-96,103,105-132,143-146,200,237-239H,21,27-34,39-76,81-84,182-185H2,1-20H3,(H2,186,240)(H2,187,241)(H2,188,242)(H2,189,243)(H2,190,244)(H,195,202)(H,196,203)(H,197,204)(H,201,255)(H,205,245)(H,206,258)(H,207,257)(H,208,260)(H,209,268)(H,210,264)(H,211,269)(H,212,281)(H,213,270)(H,214,280)(H,215,282)(H,216,285)(H,217,276)(H,218,259)(H,219,262)(H,220,272)(H,221,273)(H,222,263)(H,223,256)(H,224,265)(H,225,271)(H,226,274)(H,227,275)(H,228,261)(H,229,283)(H,230,277)(H,231,278)(H,232,284)(H,233,254)(H,234,266)(H,235,279)(H,236,267)(H,246,247)(H,248,249)(H,250,251)(H,252,253)(H,286,287)(H4,191,192,198)(H4,193,194,199)/t96-,103-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,143-,144-,145-,146-/m0/s1 N Key:OGBMKVWORPGQRR-UMXFMPSGSA-N N
NY  (what is this?)    (verify)

Teriparatide, sold under the brand name Forteo, is a form of parathyroid hormone (PTH) consisting of the first (N-terminus) 34 amino acids, which is the bioactive portion of the hormone. ^[50] It is an effective anabolic (promoting bone formation) agent ^[52] used in the treatment of some forms of osteoporosis. ^{[50] [53]} Teriparatide is a recombinant human parathyroid hormone analog (PTH 1-34). ^[50] It has an identical sequence to the 34 N-terminal amino acids of the 84-amino acid human parathyroid hormone. ^[50]

See also

• Disorders of calcium metabolism
• Parathyroid hormone family
• Parathyroid hormone-related protein

Footnote

1. This reduction in the rate of calcium excretion via the urine is a minor effect of high parathyroid hormone levels in the blood. The main determinant of the amount of calcium excreted into the urine per day is the plasma ionized calcium concentration itself. The plasma parathyroid hormone (PTH) concentration only increases or decreases the amount of calcium excreted at any specified plasma ionized calcium concentration. Thus, in primary hyperparathyroidism, the quantity of calcium excreted in the urine per day is increased despite the high levels of PTH in the blood, because hyperparathyroidism results in hypercalcemia, which increases the urinary calcium concentration (hypercalcuria) despite the moderately increased rate of calcium reabsorption from the renal tubular fluid caused by PTH's direct effect on those tubules. Renal stones are, therefore, often a first indication of hyperparathyroidism, especially since the hypercalcuria is accompanied by an increase in urinary phosphate excretion (a direct result of the high plasma PTH levels). Together the calcium and phosphate tend to precipitate out as water-insoluble salts, which readily form solid "stones". ^{[11] [18] [19]}

References

1. GRCh38: Ensembl release 89: ENSG00000152266 - Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000059077 - Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Coetzee M, Kruger MC (May 2004). "Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?". Southern Medical Journal. 97 (5): 506–11. doi:10.1097/00007611-200405000-00018. PMID   15180028. S2CID   45131847.
6. Brewer HB, Fairwell T, Ronan R, Sizemore GW, Arnaud CD (1972). "Human parathyroid hormone: amino-acid sequence of the amino-terminal residues 1-34". Proceedings of the National Academy of Sciences of the United States of America. 69 (12): 3585–8. Bibcode:1972PNAS...69.3585B. doi: 10.1073/pnas.69.12.3585 . PMC   389826 . PMID   4509319.
7. Nosek TM. "Section 5/5ch6/s5ch6_11". Essentials of Human Physiology. Archived from the original on 24 March 2016.
8. Bieglmayer C, Prager G, Niederle B (October 2002). "Kinetic analyses of parathyroid hormone clearance as measured by three rapid immunoassays during parathyroidectomy". Clinical Chemistry. 48 (10): 1731–8. doi: 10.1093/clinchem/48.10.1731 . PMID   12324490. Archived from the original on 7 June 2011. Retrieved 23 February 2009.
9. Jin L, Briggs SL, Chandrasekhar S, Chirgadze NY, Clawson DK, Schevitz RW, et al. (September 2000). "Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolution". The Journal of Biological Chemistry. 275 (35): 27238–44. doi: 10.1074/jbc.M001134200 . PMID   10837469.
10. PDB: 1ETE ​; Savvides SN, Boone T, Andrew Karplus P (June 2000). "Flt3 ligand structure and unexpected commonalities of helical bundles and cystine knots". Nature Structural Biology. 7 (6): 486–91. doi:10.1038/75896. PMID   10881197.
11. Blaine J, Chonchol M, Levi M (2015). "Renal control of calcium, phosphate, and magnesium homeostasis". Clinical Journal of the American Society of Nephrology. 10 (7): 1257–72. doi:10.2215/CJN.09750913. PMC   4491294 . PMID   25287933.
12. Brini M, Ottolini D, Calì T, Carafoli E (2013). "Chapter 4. Calcium in Health and Disease". In Sigel A, Helmut RK (eds.). Interrelations between Essential Metal Ions and Human Diseases. Metal Ions in Life Sciences. Vol. 13. Springer. pp. 81–137. doi:10.1007/978-94-007-7500-8_4. PMID   24470090.
13. Walter F (2003). "The Parathyroid Glands and Vitamin D". Medical Physiology: A Cellular And Molecular Approach. Elsevier/Saunders. p. 1094. ISBN   1-4160-2328-3.
14. Guyton A (1976). ‘’Medical Physiology’’. p.1062; New York, Saunders and Co.
15. Barrett KE, Barman SM, Boitano S, Brooks H. "Chapter 23. Hormonal Control of Calcium & Phosphate Metabolism & the Physiology of Bone". In Barrett KE, Barman SM, Boitano S, Brooks H (eds.). Ganong's Review of Medical Physiology (23e ed.). Archived from the original on 7 July 2011. Retrieved 3 January 2016.
16. Poole KE, Reeve J (December 2005). "Parathyroid hormone - a bone anabolic and catabolic agent". Current Opinion in Pharmacology. 5 (6): 612–7. doi:10.1016/j.coph.2005.07.004. PMID   16181808.
17. Bord S, Ireland DC, Beavan SR, Compston JE (2003). "The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts". Bone. 32 (2): 136–41. doi:10.1016/S8756-3282(02)00953-5. PMID   12633785.
18. Harrison TR, Adams RD, Bennett IL, Resnick WH, Thorn GW, Wintrobe MM (1958). "Metabolic and Endocrine Disorders". Principles of Internal Medicine (Third ed.). New York: McGraw-Hill Book Company. pp. 575–578.
19. "Symptoms of Hyperparathyroidism and Symptoms of Parathyroid Disease". Parathyroid.com. Norman Parathyroid Center. Retrieved 30 December 2015.
20. Haldimann B, Vogt K (1983). "[Hyperphosphatemia and tetany following phosphate enema]". Schweizerische Medizinische Wochenschrift (in French). 113 (35): 1231–3. PMID   6623048.
21. Sutters M, Gaboury CL, Bennett WM (1996). "Severe hyperphosphatemia and hypocalcemia: a dilemma in patient management". Journal of the American Society of Nephrology. 7 (10): 2056–61. doi:10.1681/ASN.V7102056. PMID   8915965.
22. Stryer L (1995). Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. p. 707. ISBN   978-0-7167-2009-6.
23. Gardner D, Shoback D (2011). Greenspan's Basic & Clinical Endocrinology (9th ed.). McGraw Hill. p. 232. ISBN   978-0-07-162243-1.
24. Agus ZS (July 1999). "Hypomagnesemia". Journal of the American Society of Nephrology. 10 (7): 1616–22. doi: 10.1681/ASN.V1071616 . PMID   10405219.
25. Costanzo LS (2007). BRS Physiology . Lippincott, Williams, & Wilkins. pp.  260. ISBN   978-0-7817-7311-9.
26. Blaine J, Chonchol M, Levi M (July 2015). "Renal control of calcium, phosphate, and magnesium homeostasis". Clinical Journal of the American Society of Nephrology. 10 (7): 1257–72. doi:10.2215/CJN.09750913. PMC   4491294 . PMID   25287933.
27. Carrillo-López N, Fernández-Martín JL, Cannata-Andía JB (1 April 2009). "[The role of calcium, calcitriol and their receptors in parathyroid regulation]". Nefrologia. 29 (2): 103–8. doi:10.3265/Nefrologia.2009.29.2.5154.en.full. PMID   19396314.
28. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. (May 2001). "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis". The New England Journal of Medicine. 344 (19): 1434–41. doi: 10.1056/NEJM200105103441904 . PMID   11346808.
29. "Parathyroid hormone (PTH) unit conversion (online calculator)". Unitslab.
30. Longo DL, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J (2012). Harrison's Principles of Internal Medicine (18th ed.). New York: McGraw-Hill. p. 3594. ISBN   978-0-07-174889-6.
31. "Division of Laboratory Medicine: Parathyroid hormone" (PDF). Manchester University NHS Foundation Trust (UK). Archived from the original (PDF) on 2 February 2023. Retrieved 23 April 2022.
32. Zieve D. "MedlinePlus Medical Encyclopedia: Serum calcium". National Library of Medicine, National Institutes of Health. Retrieved 1 February 2009.
33. PTH, Intact and Calcium Test Detail. Quest Diagnostics Lab. Accessed 2019-06-29.
34. Parathyroid Hormone (PTH) Plus Calcium. LabCorp. Accessed 2019-07-02.
35. "Natpara (parathyroid hormone)- parathyroid hormone injection, powder, lyophilized, for solution". DailyMed. Retrieved 8 May 2021.
36. "FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism". U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 30 January 2015. Retrieved 30 January 2015. This article incorporates text from this source, which is in the public domain.
37. "Natpar EPAR". European Medicines Agency. 18 December 2013. Retrieved 28 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
38. Kim ES, Keating GM (July 2015). "Recombinant Human Parathyroid Hormone (1-84): A Review in Hypoparathyroidism". Drugs. 75 (11): 1293–303. doi:10.1007/s40265-015-0438-2. PMID   26177893. S2CID   2074875.
39. "Preotact EPAR". European Medicines Agency. 17 September 2018. Retrieved 3 July 2020.
40. "First hormone replacement therapy for parathyroid disorder". European Medicines Agency (EMA) (Press release). 24 February 2017. Retrieved 29 December 2023.
41. "Drug Approval Package: Bonsity". U.S. Food and Drug Administration (FDA). 26 February 2020. Archived from the original on 2 April 2021. Retrieved 14 September 2020.
42. "Kauliv EPAR". European Medicines Agency (EMA). 18 July 2022. Archived from the original on 9 March 2023. Retrieved 8 March 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
43. "Livogiva EPAR". European Medicines Agency (EMA). 26 May 2020. Archived from the original on 30 January 2021. Retrieved 25 January 2021.
44. "Summary Basis of Decision (SBD) for Osnuvo". Health Canada . 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
45. "Qutavina EPAR". European Medicines Agency (EMA). 26 May 2020. Archived from the original on 30 January 2021. Retrieved 25 January 2021.
46. "Sondelbay EPAR". European Medicines Agency. 24 January 2022. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
47. Lisbeth Tristan de Brea (18 September 2018). "Nota de Seguridad de Medicamentos" (PDF). Panama: Directora Nacional de Farmacia y Drogas. Archived (PDF) from the original on 4 December 2020. Retrieved 30 September 2018.
48. "Teriparatide Use During Pregnancy". Drugs.com. 25 November 2019. Archived from the original on 27 October 2020. Retrieved 14 September 2020.
49. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
50. "Forteo- teriparatide injection, solution". DailyMed. 29 April 2021. Archived from the original on 19 January 2022. Retrieved 8 March 2023.
51. "Forsteo EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 27 June 2020. Retrieved 26 June 2020.
52. Riek AE, Towler DA (2011). "The pharmacological management of osteoporosis". Missouri Medicine. 108 (2): 118–23. PMC   3597219 . PMID   21568234.
53. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, et al. (November 2007). "Teriparatide or alendronate in glucocorticoid-induced osteoporosis". The New England Journal of Medicine. 357 (20): 2028–39. doi: 10.1056/NEJMoa071408 . PMID   18003959.

Further reading

• Drüeke TB, Massy ZA (2003). "Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia". Blood Purification. 20 (5): 494–7. doi:10.1159/000065203. PMID   12207101. S2CID   46752152.
• Parfitt AM (October 2002). "Parathyroid hormone and periosteal bone expansion". Journal of Bone and Mineral Research. 17 (10): 1741–3. doi:10.1359/jbmr.2002.17.10.1741. PMID   12369776. S2CID   37111637.
• Martin TJ (March 2004). "Does bone reabsorption inhibition affect the anabolic response to parathyroid hormone?". Trends in Endocrinology and Metabolism. 15 (2): 49–50. doi:10.1016/j.tem.2004.01.002. PMID   15080150. S2CID   35482527.
• Keutmann HT, Sauer MM, Hendy GN, O'Riordan LH, Potts JT (December 1978). "Complete amino acid sequence of human parathyroid hormone". Biochemistry. 17 (26): 5723–9. doi:10.1021/bi00619a019. PMID   728431.
• Keutmann HT, Niall HD, O'Riordan JL, Potts JT (May 1975). "A reinvestigation of the amino-terminal sequence of human parathyroid hormone". Biochemistry. 14 (9): 1842–7. doi:10.1021/bi00680a006. PMID   1125201.
• Parkinson DB, Thakker RV (May 1992). "A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism". Nature Genetics. 1 (2): 149–52. doi:10.1038/ng0592-149. PMID   1302009. S2CID   24032313.
• Handt O, Reis A, Schmidtke J (November 1992). "Ectopic transcription of the parathyroid hormone gene in lymphocytes, lymphoblastoid cells and tumour tissue". The Journal of Endocrinology. 135 (2): 249–56. doi:10.1677/joe.0.1350249. PMID   1474331.
• Tonoki H, Narahara K, Matsumoto T, Niikawa N (1991). "Regional mapping of the parathyroid hormone gene (PTH) by cytogenetic and molecular studies". Cytogenetics and Cell Genetics. 56 (2): 103–4. doi:10.1159/000133059. PMID   1672845.
• Marx UC, Adermann K, Bayer P, Meyer M, Forssmann WG, Rösch P (February 1998). "Structure-activity relation of NH2-terminal human parathyroid hormone fragments". The Journal of Biological Chemistry. 273 (8): 4308–16. doi: 10.1074/jbc.273.8.4308 . PMID   9468478. S2CID   1009667.
• Arnold A, Horst SA, Gardella TJ, Baba H, Levine MA, Kronenberg HM (October 1990). "Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism". The Journal of Clinical Investigation. 86 (4): 1084–7. doi:10.1172/JCI114811. PMC   296835 . PMID   2212001.
• Nussbaum SR, Gaz RD, Arnold A (November 1990). "Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone". The New England Journal of Medicine. 323 (19): 1324–8. doi: 10.1056/NEJM199011083231907 . PMID   2215618.
• Ahn TG, Antonarakis SE, Kronenberg HM, Igarashi T, Levine MA (March 1986). "Familial isolated hypoparathyroidism: a molecular genetic analysis of 8 families with 23 affected persons". Medicine. 65 (2): 73–81. doi: 10.1097/00005792-198603000-00001 . PMID   3005800. S2CID   25332134.
• Tregear GW, van Rietschoten J, Greene E, Niall HD, Keutmann HT, Parsons JA, et al. (April 1974). "Solid-phase synthesis of the biologically active N-terminal 1 - 34 peptide of human parathyroid hormone". Hoppe-Seyler's Zeitschrift für Physiologische Chemie. 355 (4): 415–21. doi:10.1515/bchm2.1974.355.1.415. PMID   4474131. S2CID   43509130.
• Niall HD, Sauer RT, Jacobs JW, Keutmann HT, Segre GV, O'Riordan JL, et al. (February 1974). "The amino-acid sequence of the amino-terminal 37 residues of human parathyroid hormone". Proceedings of the National Academy of Sciences of the United States of America. 71 (2): 384–8. Bibcode:1974PNAS...71..384N. doi: 10.1073/pnas.71.2.384 . PMC   388010 . PMID   4521809.
• Andreatta RH, Hartmann A, Jöhl A, Kamber B, Maier R, Riniker B, et al. (1973). "[Synthesis of sequence 1-34 of human parathyroid hormone]". Helvetica Chimica Acta. 56 (1): 470–3. doi:10.1002/hlca.19730560139. PMID   4721748.
• Jacobs JW, Kemper B, Niall HD, Habener JF, Potts JT (May 1974). "Structural analysis of human proparathyroid hormone by a new microsequencing approach". Nature. 249 (453): 155–7. Bibcode:1974Natur.249..155J. doi:10.1038/249155a0. PMID   4833516. S2CID   4226663.
• Vasicek TJ, McDevitt BE, Freeman MW, Fennick BJ, Hendy GN, Potts JT, et al. (April 1983). "Nucleotide sequence of the human parathyroid hormone gene". Proceedings of the National Academy of Sciences of the United States of America. 80 (8): 2127–31. Bibcode:1983PNAS...80.2127V. doi: 10.1073/pnas.80.8.2127 . PMC   393770 . PMID   6220408.
• Mayer H, Breyel E, Bostock C, Schmidtke J (1983). "Assignment of the human parathyroid hormone gene to chromosome 11". Human Genetics. 64 (3): 283–5. doi:10.1007/BF00279412. PMID   6885073. S2CID   35197648.
• Hendy GN, Kronenberg HM, Potts JT, Rich A (December 1981). "Nucleotide sequence of cloned cDNAs encoding human preproparathyroid hormone". Proceedings of the National Academy of Sciences of the United States of America. 78 (12): 7365–9. Bibcode:1981PNAS...78.7365H. doi: 10.1073/pnas.78.12.7365 . PMC   349267 . PMID   6950381.
• Hendy GN, Bennett HP, Gibbs BF, Lazure C, Day R, Seidah NG (April 1995). "Proparathyroid hormone is preferentially cleaved to parathyroid hormone by the prohormone convertase furin. A mass spectrometric study". The Journal of Biological Chemistry. 270 (16): 9517–25. doi: 10.1074/jbc.270.16.9517 . PMID   7721880. S2CID   10879253.

External links

• Media related to Parathyroid hormone at Wikimedia Commons
• Parathyroid hormone: analyte monograph - the Association for Clinical Biochemistry and Laboratory Medicine
• Overview of all the structural information available in the PDB for UniProt : P01270 (Parathyroid hormone) at the PDBe-KB .